Sanofi is calling on the FDA to change the labels for CSL Limited subsidiary Seqirus’ flu vaccines, which won accelerated approvals but have failed to confirm clinical benefit.
In a crowded flu vaccine market, in which Sanofi’s flu business pulled in more than $2.8 billion in 2021, two of Seqirus’ flu vaccines include Fluad, which is an adjuvanted seasonal aTIV vaccine that won accelerated approval in Nov. 2015, and Fluad Quadrivalent, which is a formulation of the original that won accelerated approval via an sBLA in Feb. 2020.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 135,000+ biopharma pros reading Endpoints daily — and it’s free.
from WordPress https://ift.tt/2uV4WGE
via IFTTT
No comments:
Post a Comment